New approach targets DNA damage
Scientists at King's College London have found that an experimental drug called KCL-286, originally developed for spinal cord injury, repairs DNA damage and reduces inflammation in the brains of mice with Alzheimer's disease. Unlike most current treatments that target amyloid plaques or tau tangles, KCL-286 addresses multiple early biological changes simultaneously — including DNA damage and neuroinflammation, both of which appear in the earliest stages of the disease.
The drug works by activating the retinoic acid receptor-beta (RARβ), which triggers a pathway that helps repair damaged DNA in neurons. Study authors described the mechanism as "repairing potholes in a road — once the damage is fixed, normal traffic can flow again and the system settles down."
Already past first safety hurdle
KCL-286 has already completed Phase 1 safety trials for spinal cord injury, meaning it could move into Alzheimer's clinical trials faster than a completely new compound. Researchers said the drug reduced neuronal inflammation and abnormal brain immune activity in the mouse models — processes that are believed to drive Alzheimer's progression.
Broader implications
Alzheimer's disease affects more than 55 million people worldwide, and current treatments offer only modest symptom relief. The KCL-286 approach represents a shift toward targeting the disease's root biological mechanisms rather than its downstream protein aggregates. If human trials confirm the mouse findings, it could open an entirely new class of Alzheimer's therapies.